AN2 Therapeutics, Inc. (ANTX)
5.69
-0.29
(-4.85%)
USD |
NASDAQ |
Sep 09, 13:39
AN2 Therapeutics Total Liabilities (Quarterly) : 5.755M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.755M |
| March 31, 2026 | 5.732M |
| December 31, 2025 | 8.89M |
| September 30, 2025 | 6.858M |
| June 30, 2025 | 6.983M |
| March 31, 2025 | 8.014M |
| December 31, 2024 | 10.24M |
| September 30, 2024 | 10.02M |
| June 30, 2024 | 10.13M |
| March 31, 2024 | 10.66M |
| Date | Value |
|---|---|
| December 31, 2023 | 14.04M |
| September 30, 2023 | 14.84M |
| June 30, 2023 | 11.16M |
| March 31, 2023 | 8.567M |
| December 31, 2022 | 7.188M |
| September 30, 2022 | 4.435M |
| June 30, 2022 | 4.153M |
| March 31, 2022 | 5.093M |
| December 31, 2021 | 3.408M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 3.605M |
| CNBX Pharmaceuticals, Inc. | 2.672M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 112.90M |
| Fulcrum Therapeutics, Inc. | 13.26M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 81.68M |
| Shareholders Equity (Quarterly) | 75.92M |
| Current Ratio | 14.32 |